Using blood markers to predict nerve invasion in pancreatic cancer
Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer
This study is trying to see if certain blood markers can help predict nerve invasion in patients with pancreatic cancer to improve their treatment plans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 323 (estimated) |
| Sex | All |
| Sponsor | University of Las Palmas de Gran Canaria Academic / other |
| Locations | 1 site (Las Palmas de Gran Canaria, Las Palmas) |
| Trial ID | NCT06747481 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the neutrophil-to-lymphocyte ratio and CA 19.9 levels as potential predictors of perineural invasion in patients with pancreatic cancer. By analyzing preoperative blood counts and CA 19.9 levels in patients diagnosed with adenocarcinoma who have undergone surgical resection, the study seeks to identify key prognostic factors that could influence clinical management. The focus is on understanding how these markers correlate with perineural invasion, which is a significant factor affecting patient prognosis. The findings could help in risk stratification and treatment planning for pancreatic cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults with a histopathological diagnosis of pancreatic adenocarcinoma who are scheduled for surgical resection.
Not a fit: Patients with other histological types of pancreatic cancer or those who have incomplete data will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the ability to predict perineural invasion in pancreatic cancer, leading to better treatment strategies and outcomes for patients.
How similar studies have performed: While the specific combination of neutrophil-to-lymphocyte ratio and CA 19.9 as predictors of perineural invasion is novel, similar studies have explored prognostic factors in pancreatic cancer with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with a histopathological diagnosis of adenocarcinoma. * Surgical resection of the neoplasm. * Preoperative blood count allowing calculation of the neutrophil-to-lymphocyte ratio and preoperative CA 19.9, both before and after neoadjuvant therapy. Exclusion Criteria: * Patients with a diagnosis of another histological type. * Patients with incomplete data. * Patients who were not operated on.
Where this trial is running
Las Palmas de Gran Canaria, Las Palmas
- University Hospital of Gran Canaria Doctor Negrín — Las Palmas de Gran Canaria, Las Palmas, Spain (Recruiting)
Study contacts
- Study coordinator: Pau Plá Sánchez
- Email: paups88@gmail.com
- Phone: 34 620541910
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.